- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
Patent holdings for IPC class A61K 47/65
Total number of patents in this class: 1643
10-year publication summary
50
|
65
|
123
|
210
|
211
|
200
|
198
|
213
|
241
|
77
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
The Regents of the University of California | 19784 |
29 |
SeaGen Inc | 578 |
25 |
Daiichi Sankyo Company, Limited | 1849 |
23 |
Bayer Pharma AG | 1061 |
20 |
Bicyclerd Limited | 142 |
17 |
SynDevRx, Inc. | 46 |
16 |
CytomX Therapeutics, Inc. | 215 |
15 |
Shanghai Hengrui Pharmaceutical Co., Ltd. | 629 |
15 |
Genentech, Inc. | 3935 |
14 |
MedImmune Limited | 607 |
14 |
Genequantum Healthcare (Suzhou) Co., Ltd. | 59 |
14 |
Cornell University | 3272 |
12 |
ImmunoGen, Inc. | 398 |
12 |
Bristol-myers Squibb Company | 4896 |
11 |
The Johns Hopkins University | 5628 |
11 |
Duke University | 3056 |
10 |
Purdue Research Foundation | 3557 |
10 |
Blaze BioScience, Inc. | 77 |
10 |
Case Western Reserve University | 1790 |
10 |
Immunwork Inc. | 25 |
10 |
Other owners | 1345 |